Omeros(US:OMER) Ge Long Hui·2025-12-26 10:06Core Viewpoint - Omeros Corporation (OMER.US) experienced a pre-market decline of 4.95% to $14.60 after a significant increase of 75.54% in the previous trading session, where the stock price reached a new high not seen since May 2021. This fluctuation follows the FDA's approval of YARTEMLEA (narsoplimab-wuug) for treating thrombotic microangiopathy (TA-TMA) related to hematopoietic stem cell transplantation, marking it as the first and only approved complement pathway inhibitor [1][1][1]. Group 1 - The stock closed at $15.36 with a substantial increase of 75.54% on December 24, 2023 [1]. - The pre-market price on December 26, 2023, was $14.60, reflecting a decrease of $0.76 or 4.95% [1]. - The stock reached a high of $17.65 and a low of $13.92 during the trading session, with a trading volume of approximately 24.51 million shares [1][1]. Group 2 - The total market capitalization of Omeros Corporation is approximately $1.089 billion [1]. - The stock has a 52-week high of $17.65 and a low of $2.95, indicating significant volatility [1]. - The average price during the trading session was $15.423, with a turnover rate of 35.94% [1].